Adial's PK study satisfied an FDA requirement for the AD04 Phase 3 trial. Study confirmed AD04 can be taken with or without ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...

Adial Pharmaceuticals (ADIL) announced that it has completed a pharmacokinetics, PK, study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, and ...

The publication findings showed a significant difference in the monthly percentage of heavy drinking days between the company's lead asset, AD04 (low-dose ondansetron), and the placebo group among ...

The patent, once issued, will expand Adial’s intellectual property protection around its lead investigational drug, AD04, ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 78,900 shares, a ...

AD04, Adial’s lead investigational product for alcohol use disorder (AUD), is designed to support patients seeking flexible treatment that could offer reduction in drinking and/or abstinence ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...

Adial Pharmaceuticals receives a Notice of Allowance for a new patent expanding intellectual property for AD04 for alcohol use disorder. Topline results from AD04's pharmacokinetics study in heavy ...

It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.